RadioMedix received $2 M SBIR Phase II Contract award from NCI NIH for the targeted alpha-emitter therapy of neuroendocrine cancers (en anglais)

21 janvier 2019

Houston, Texas (USA)

RadioMedix Inc. is pleased to announce that the company has been awarded a two-year, $2.0 M Phase II SBIR contract award by the NIH NCI (HHSN261201800048C; UPIID:75N91018C00048) for the clinical development of Targeted Alpha-emitter Therapy (TAT) of neuroendocrine tumors. This Phase II Contract award is a continuation of the successfully completed Phase I SBIR contract (HHSN261201600015C). This award will support the Phase I, non-randomized, open-label, dose escalation study to determine the safety, bio-distribution, and preliminary effectiveness of 212Pb-octreotate analog (AlphaMedix™) in adult subjects with Somatostatin Receptor (SSTR) expressing neuroendocrine tumors (NCT03466216). Dr. Izabela Tworowska (RadioMedix) serves as a Principal Investigator of the SBIR Phase II contract and is working together with Dr. Julien Torgue (co-I, Orano Med). The clinical studies are currently on-going at the Excel Diagnostics and Nuclear Oncology Center (Houston, TX).

Click here to read the full article.  Follow @OranoMed on Twitter.

Vidéo Orano Med

Cliquez ici pour voir la vidéo


Pour plus d'informations à propos d'Orano Med, veuillez contacter :
Alison Tise
Tel.: + 1 (301) 841-1673